Stuart Hughes is now CEO of Pathios Therapeutics Ltd. He was senior director and head of pharmacology at Vertex Pharmaceuticals (Europe) Ltd. Pathios is an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer.

Rekha Hemrajani has been named president, CEO, and director of Aravive Inc. Jay Shepard, who last year announced plans to step down as Aravive’s CEO, will transition to the role of chairman of the board of directors. Prior to joining Aravive, Hemrajani served as chief operating officer and chief financial officer of Arcus Biosciences Inc. Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis.

James Burns, Ph.D., has been appointed CEO of Locana Inc. Dr. Burns was CEO of Casebia. Locana is a leading RNA-targeting gene therapy company.

Ken Horne has become president and chief operating officer of Teon Therapeutics. He was the CEO of Symic Bio. Teon Therapeutics is developing novel small molecules focused on GPCR targets for oncology indications.

Craig Tooman is now the chief operating officer and chief financial officer of Vyome Therapeutcs. Tooman was CEO of Aratana Therapeutics. Vyome is a clinical-stage specialty pharmaceutical company working to treat inflammatory diseases of unmet need with locally acting, next-generation therapeutic solutions.

Onaiza Cadoret-Manier was made chief corporate development and commercial officer at Ionis Pharmaceuticals Inc. Before joining Ionis, Cadoret-Manier was the chief commercial officer for Grail Biosciences. Ionis is a leader in RNA-targeted drug discovery and development.

Jason Hoitt is now chief commercial officer of Provention Bio Inc. Hoitt was chief commercial officer at Dova Pharmaceuticals. Provention is a clinical-stage biopharmaceutical company focused on the prevention or interception of immune-mediated disease.

James Hassard was appointed chief commercial officer of Arrowhead Pharmaceuticals Inc. Hassard was senior VP of marketing and market access at Coherus BioSciences. Arrowhead is developing a pipeline of RNAi therapeutics.

Kirsten Flowers has become chief commercial officer of Kura Oncology Inc. Flowers joins Kira from Array BioPharma where she was head of commercial operations. Kura is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer.

Jennifer Chien was appointed to the newly created position of chief commercial officer at Krystal Biotech Inc. (Nasdaq: KRYS), effective Jan. 20, 2020. Chien has more than 20 years of commercial leadership experience in the biopharmaceutical industry, most recently having served as VP, head of genetic diseases at Sanofi Genzyme. Krystal Biotech is a gene therapy company developing medicines to treat rare diseases.

John Chin is now chief business officer of Antengene Corp., reporting directly to Chairman and CEO Dr. Jay Mei. Chin was country general manager for Celgene China. Antengene is a China and U.S.-based biopharmaceutical company focusing on drug discovery, clinical development, and the commercialization of innovative therapeutics to meet unmet medical needs in oncology.

Michael A. Nazak was made chief financial officer of Aridis Pharmaceuticals Inc. He was serving as VP, finance, and replaces Fred Kurland, who has chosen to retire. Aridis discovers and develops anti-infectives with mechanisms of action that are different from antibiotics.

Sara Bonstein has become chief financial officer of Insmed Inc. She was most recently chief financial officer and chief operating officer of OncoSec Medical Inc. Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.

Maged Shenouda has been appointed Relmada Therapeutics Inc.’s new chief financial officer. Shenouda stepped down from the company’s board of directors to join the executive management team. Charles Ence, Relmada’s current chief financial officer, assumes a new role in the expanded financial team as Relmada’s chief accounting and compliance officer. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases.

Kevin Ostrander is now senior VP of business development of BioDelivery Sciences International Inc. He was head of North America business development for Glenmark Pharmaceuticals. BioDelivery Sciences is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.

Dr. Steven Hildemann has been appointed executive VP, chief medical officer, head of global medical affairs and pharmacovigilance at Ipsen. The appointment is effective March 1, 2020. Prior to joining Ipsen, Dr. Hildemann held leadership roles in science-based bioethics and built an innovative digital health startup in cancer care after serving for five years as chief medical officer, senior VP, head of Global Medical Affairs and Global Patient Safety at Merck. Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care.

Dr. Elliot Norry was made senior VP and chief medical office of Adaptimmune Therapeutics plc. Dr. Norry was acting chief medical officer. Adapatimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products.

Joan Schmidt joins Arena Pharmaceuticals as executive VP, general counsel and secretary. Steven Spector, Arena’s executive VP, general counsel and secretary, is retiring from the company after nearly two decades of service. To support the transition, Spector will remain with Arena in his current role until early March, and then will serve as a consultant supporting ongoing projects for the company. Schmidt was executive VP, chief legal officer, and secretary at DBV Technologies Inc. and executive VP and U.S. general counsel at Biotronik Inc. Arena is developing best-in-disease medicines with optimized efficacy and safety for patients globally, with a robust pipeline of novel, transformational medicines grounded in two decades of world class G-protein-coupled receptor (GPCR) discovery research.

Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Oncopeptides AB. Prior to joining Oncopeptides, she served as global regulatory director at Swedish Orphan Biovitrum. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.

Dr. Alex Jackson was made head of research and development, Archie Hale is director of clinical operations, and Dr. Daniel Stevens was appointed chief medical officer of Theragnostics. Dr. Jackson joins Theragnostics from GE Healthcare where he was responsible for the discovery phase of immune-oncology PET projects and for a multi-center late-stage clinical PET tracer development program. Hale is a seasoned pharmaceutical industry professional with extensive experience across all stages of drug development for several leading companies including Biogen, BTG, and Roche. Theragnostics’ technology platform enables the development of molecular radiotherapy based on a PARPi for imaging and treating cancer.

Adrian Adams has become chairman of the board and Sheena K. Aurora, M.D., is now VP of medical affairs – Migraine Franchise at Impel NeuroPharma Inc. Adams was CEO of Aralez Pharmaceuticals Inc. Prior to joining Impel, Dr. Aurora was a senior medical fellow, global launch leader at Eli Lilly where she supported the market introduction and medical communications of the company’s calcitonin gene-related peptide (CGRP) development platform. Impel NeuroPharma is a privately held, Seattle-based biopharmaceutical company focused on developing transformative therapies for people living with central nervous system disorders that unlock the full potential of therapeutic molecules for patients with high unmet medical needs.

Joseph Camardo, M.D., has become head of medical affairs at ADC Therapeutics SA. Dr. Camardo was senior VP of Celgene Global Health. ADC Therapeutics is a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors.

Joseph Schindler, M.D., was named to the newly created position of chief medical officer at Aeromics Inc. Dr. Schindler is an associate professor of neurology and of neurosurgery at Yale University School of Medicine where he is the clinical chief of the division of vascular neurology. In addition, he is the director of the comprehensive stroke program and Telestroke services at Yale New Haven Hospital. Aeromics is a privately held, clinical-stage pharmaceutical company dedicated to fundamentally changing the way in which various conditions resulting from the loss of water homeostasis are treated.

Howard L. Kaufman, M.D., FACS, was named head of research and development at Immuneering Corp. Dr. Kaufman was chief medical officer at Replimune Group Inc. Immuneering is developing drug candidates focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.

Eldon Mayer is now executive VP and chief commercial officer of Eiger BioPharmaceuticals Inc. He was most recently executive VP and chief commercial officer of Rigel Pharmaceuticals. Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs, for which no approved therapies exist.

Thierry Dervieux, Pharm.D., Ph.D., was made chief development officer, diagnostics, and medical laboratory director at Prometheus Biosciences Inc. Dr. Dervieux was chief scientific officer and medical director at Exagen Diagnostics. Prometheus is a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases.

Gerard DiGirolamo joins as VP, sales, and Sheila Kennedy becomes VP, marketing, at Verrica Pharmaceuticals Inc. DiGirolamo was field VP, US Dermatology, at Stiefel. Kennedy directed global and U.S. marketing at EPI Health LLC for the dermatology medication Rhofade. Verrica is a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions.